H-7 increases trabecular facility and facility after ciliary muscle disinsertion in monkeys.
OBJECTIVE
To determine the effects of the serine-threonine kinase inhibitor H-7 on total outflow facility in iridectomized + ciliary muscle (CM)- disinserted, and on trabecular facility in normal, monkey eyes.


METHODS
Total outflow facility was determined by two-level constant pressure perfusion of the anterior chamber. Trabecular outflow facility was determined from accumulation in blood of intracamerally infused radioiodinated albumin at two intraocular pressure levels.


RESULTS
Three-hundred micromoles of intracameral H-7 doubled facility in iridectomized + CM- disinserted monkey eyes and contralateral iridectomized-only eyes. Four 5-microl drops of 400 mM H-7 applied topically followed 2 hours later by anterior chamber exchange for 10 minutes and intracameral infusion for 90 minutes with 100 microM H-7 increased trabecular and total outflow facility by 135%+/-29% and 105%+/-35% (n 5, P < 0.01, P < 0.05), respectively, compared with contralateral vehicle-treated eyes.


CONCLUSIONS
H-7 increases trabecular outflow facility in monkeys by a mechanism independent of the CM, presumably acting directly on the trabecular meshwork.
Tian
B
B
Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 53792-3220, USA.
Gabelt
B T
BT
Peterson
J A
JA
Kiland
J A
JA
Kaufman
P L
PL
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000867:Anterior Chamber; D001082:Aqueous Humor / Q000378:metabolism*; D018916:Blood-Aqueous Barrier / Q000502:physiology; D002924:Ciliary Body / Q000502:physiology / Q000601:surgery*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D007498:Iris / Q000601:surgery; D008252:Macaca fascicularis; D008253:Macaca mulatta; D009130:Muscle, Smooth / Q000502:physiology / Q000601:surgery*; D009883:Ophthalmic Solutions; D010477:Perfusion; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D014129:Trabecular Meshwork / Q000187:drug effects* / Q000502:physiology
D004791:Enzyme Inhibitors; D009883:Ophthalmic Solutions; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D017346:Protein Serine-Threonine Kinases